Eton Pharmaceuticals, Inc.ETONNASDAQ
LOADING
|||
Switch Symbol:
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -70.04% |
| Q2 2025 | 219.72% |
| Q1 2025 | 233.30% |
| Q4 2024 | -272.48% |
| Q3 2024 | -83.00% |
| Q2 2024 | 356.22% |
| Q1 2024 | -37.82% |
| Q4 2023 | 70.24% |
| Q3 2023 | -45.33% |
| Q2 2023 | 110.28% |
| Q1 2023 | -43.33% |
| Q4 2022 | 26.88% |
| Q3 2022 | 7.83% |
| Q2 2022 | -57.35% |
| Q1 2022 | 137.59% |
| Q4 2021 | -74.57% |
| Q3 2021 | 34.57% |
| Q2 2021 | 124.60% |
| Q1 2021 | -73.95% |
| Q4 2020 | 20.35% |
| Q3 2020 | 75.64% |
| Q2 2020 | -74.33% |
| Q1 2020 | 2590.13% |
| Q4 2019 | -93.18% |
| Q3 2019 | 137.53% |
| Q2 2019 | -77.74% |
| Q1 2019 | 486.66% |
| Q4 2018 | -28.63% |
| Q3 2018 | -9.55% |
| Q2 2018 | 33.99% |
| Q1 2018 | -54.95% |
| Q4 2017 | 80.82% |
| Q3 2017 | 4.06% |
| Q2 2017 | 0.00% |